8-K: Cocrystal Pharma to Present Positive Phase 1 Norovirus Drug Data at International Conference

Cocrystal Pharma, Inc. announced that its first-in-class pan-viral protease inhibitor CDI-988, targeting norovirus, will be featured in an oral presentation at the 9th International Calicivirus Conference, detailing Phase 1 study results.

Summary

• Cocrystal Pharma's broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 9th International Calicivirus Conference, scheduled for September 7-11, 2025, in Banff, Alberta, Canada.
• Dr. Sam Lee, the company's President and co-CEO, will present "Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Mechanism of Action and Phase 1 Study Results" on September 11, 2025.
• Norovirus causes a highly contagious gastrointestinal illness with a substantial global economic impact, estimated at approximately $60 billion annually according to the CDC.
• There is currently no approved vaccine or antiviral therapeutic available for norovirus infection.
• CDI-988 was developed using Cocrystal's proprietary structure-based platform technology as a broad-spectrum inhibitor targeting a highly conserved region in 3CL viral proteases.
• The molecule has demonstrated novel pan-viral activity against all noroviruses, including GII.4 and GII.17 strains, and also targets coronaviruses.
• A single-center, randomized, double-blind, placebo-controlled Phase 1 study in healthy adults, evaluating the safety, tolerability, and pharmacokinetics of CDI-988 (including a food effect cohort), has been completed.

Sentiment

Score: 7

Explanation: The announcement is largely positive, detailing progress on a first-in-class drug candidate and its upcoming presentation at a key scientific conference, addressing a significant unmet medical need. The completion of Phase 1 is a positive development milestone. However, the early stage of the drug's development and the explicit mention of the need for additional capital temper the overall sentiment, indicating continued financial and clinical risks.

Positives

• CDI-988 is described as a "first-in-class" pan-viral protease inhibitor, addressing an unmet medical need for norovirus treatment.
• The molecule exhibits novel pan-viral activity against all noroviruses, including prevalent GII.4 and GII.17 strains, and also shows activity against coronaviruses.
• The completion of a Phase 1 study in healthy adults, evaluating safety, tolerability, and pharmacokinetics, marks a significant development milestone.
• The drug was designed using Cocrystal's proprietary structure-based platform technology, which aims to develop best-in-class antiviral therapies with desirable attributes such as fast onset, shortened treatment time, safety, tolerability, ease of administration, broad effectiveness against viral subtypes, and a high barrier to viral resistance.
• The selection for an oral presentation at the 9th International Calicivirus Conference provides a prominent platform to share Phase 1 data and clinical development strategy with leading experts.

Risks

• The company requires additional capital to fund its operations over the next 12 months.
• Risks are associated with obtaining regulatory approval for and proceeding with clinical trials, including challenges in recruiting volunteers and procuring materials from clinical research organizations and vendors.
• The results of clinical studies are uncertain and may not be favorable.
• There is a risk that the company's and its collaboration partners' technology and software may not perform as expected.
• General risks inherent in clinical studies exist.
• Regulatory changes could impact development timelines or requirements.
• Competitors may develop effective treatments and/or vaccines, potentially impacting market opportunity.
• Potential mutations in targeted viruses could result in variants resistant to developed product candidates.
• Government policies and actions, such as those affecting the FDA and other healthcare agencies, including potential staffing issues or tariffs, may cause delays or incur additional costs for development programs.

Future Outlook

The company aims to develop best-in-class antiviral therapies characterized by fast onset of action, shortened treatment time, safety, tolerability, ease of administration, effectiveness against all viral subtypes, and a high barrier to viral resistance, leveraging its proprietary structure-based platform technology. The upcoming presentation of Phase 1 data for CDI-988 is a key step towards its potential future clinical development and regulatory approval as a treatment for norovirus and coronaviruses.

Management Comments

• "This year's Calicivirus Conference will bring together the world's leading norovirus experts, making it the ideal venue to share our pan-viral protease inhibitor CDI-988 Phase 1 data and clinical development strategy." Dr. Sam Lee, President and co-CEO.
• "We are encouraged by our molecule's novel pan-viral activity against all noroviruses including GII.4 and GII.17 strains." Dr. Sam Lee.

Industry Context

The announcement highlights a significant unmet medical need, as there are currently no approved vaccines or antiviral therapeutics for norovirus infection, a highly contagious gastrointestinal illness with an estimated global societal cost of $60 billion annually. Cocrystal Pharma is positioning CDI-988 as a potential first-in-class oral treatment to address this gap, also noting its pan-viral activity against coronaviruses. The presentation at a major international conference for calicivirus experts underscores the company's engagement with the scientific community and its efforts to advance solutions in this critical public health area.

Comparison to Industry Standards

• The document explicitly states, "There is no approved vaccine or antiviral therapeutics for norovirus infection," indicating that CDI-988, if successfully developed, would be a pioneering treatment in this specific therapeutic area, establishing a new standard.
• The company's goal to develop "best-in-class antiviral therapies" with attributes such as fast onset, shortened treatment time, safety, tolerability, ease of administration, effectiveness against all viral subtypes, and a high barrier to viral resistance aligns with general industry objectives for advanced antiviral drug development.
• No specific comparable companies, projects, or existing treatments are mentioned for direct quantitative or qualitative comparison within the document.

Stakeholder Impact

• Shareholders: Potential positive impact from progress in drug development and increased visibility, but also exposure to risks associated with the need for additional capital and general clinical trial uncertainties.
• Patients/Public Health: Significant potential positive impact if CDI-988 proves effective, as it addresses a major public health issue with no current approved treatments.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline.
• Regulatory Authorities: Will be involved in future approvals and oversight of clinical trials as the drug progresses.

Next Steps

• Oral presentation of CDI-988 Phase 1 study results by Dr. Sam Lee at the 9th International Calicivirus Conference on September 11, 2025.
• Further clinical development of CDI-988 for norovirus and coronaviruses, following the Phase 1 study results.

Key Dates

Recommendation

Keywords

Norovirus, CDI-988, Antiviral, Protease Inhibitor, Phase 1, Clinical Trial, Biotechnology, Calicivirus, Drug Development, Cocrystal Pharma, COCP, SARS-CoV-2, Coronavirus, Influenza, Hepatitis C